Overview

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This clinical study is to determine the optimum dose of PAC-14028 cream in a therapeutic confirmatory clinical study by evaluating the safety and therapeutic equivalence of PAC-14028 cream 0.1%, 0.3% and 1.0% in patients with rosacea.
Phase:
Phase 2
Details
Lead Sponsor:
Amorepacific Corporation